To be clear, that concern was well-founded: High drug prices are one reason the U.S. has become a global leader in medical innovation. Some of the most important advancements in the field — from ...

Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of ...

From 2015 and 2021, almost 30% of deaths among residents and fellows were due to suicide. In other news: Medicare fraud at UnitedHealth; patient fall rates at rehab facilities; and more.

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...

CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

Denmark’s economic growth, which was driven by what economists described as an “exceptional surge” in pharmaceutical exports, ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

Health-care companies fell amid concerns about increased regulation and upheaval in the sector. UnitedHealth Group continued its retreat after the abrupt departure of its chief executive.

The e-methanol plant, built by European Energy & Mitsui, will supply companies including Maersk, LEGO & Novo Nordisk with ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.